Insider Selling: Biohaven Pharmaceutical Holding Co Ltd (BHVN) VP Sells 5,000 Shares of Stock

Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) VP Kimberly Gentile sold 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $27.60, for a total value of $138,000.00. Following the completion of the sale, the vice president now owns 5,000 shares in the company, valued at approximately $138,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Kimberly Gentile also recently made the following trade(s):

  • On Friday, December 1st, Kimberly Gentile sold 5,000 shares of Biohaven Pharmaceutical stock. The shares were sold at an average price of $21.99, for a total value of $109,950.00.
  • On Wednesday, November 1st, Kimberly Gentile sold 5,000 shares of Biohaven Pharmaceutical stock. The shares were sold at an average price of $29.28, for a total value of $146,400.00.

Shares of Biohaven Pharmaceutical Holding Co Ltd (NYSE BHVN) traded up $0.33 during midday trading on Wednesday, hitting $28.42. The stock had a trading volume of 289,788 shares, compared to its average volume of 241,650. The company has a market capitalization of $1,010.00 and a price-to-earnings ratio of -5.44. Biohaven Pharmaceutical Holding Co Ltd has a one year low of $17.00 and a one year high of $39.51.

Several analysts have issued reports on BHVN shares. BidaskClub upgraded Biohaven Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research note on Thursday, September 7th. Zacks Investment Research upgraded Biohaven Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Friday, September 8th. Piper Jaffray Companies restated a “buy” rating and issued a $54.00 price objective on shares of Biohaven Pharmaceutical in a research note on Tuesday, September 12th. Needham & Company LLC restated a “buy” rating and issued a $43.00 price objective (up previously from $30.00) on shares of Biohaven Pharmaceutical in a research note on Wednesday, September 13th. Finally, Morgan Stanley upped their price objective on Biohaven Pharmaceutical from $28.00 to $47.00 and gave the company an “overweight” rating in a research note on Monday, September 25th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company’s stock. Biohaven Pharmaceutical currently has an average rating of “Buy” and an average target price of $36.14.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. VHCP Management II LLC bought a new position in shares of Biohaven Pharmaceutical during the third quarter worth approximately $60,826,000. Eagle Asset Management Inc. bought a new position in shares of Biohaven Pharmaceutical during the third quarter worth approximately $32,635,000. Janus Henderson Group PLC bought a new position in shares of Biohaven Pharmaceutical during the third quarter worth approximately $25,751,000. JPMorgan Chase & Co. bought a new position in shares of Biohaven Pharmaceutical during the third quarter worth approximately $18,173,000. Finally, Stifel Financial Corp bought a new position in shares of Biohaven Pharmaceutical during the third quarter worth approximately $15,525,000. Institutional investors own 47.76% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another website, it was copied illegally and reposted in violation of US and international trademark and copyright legislation. The original version of this piece of content can be read at https://www.americanbankingnews.com/2018/01/03/insider-selling-biohaven-pharmaceutical-holding-co-ltd-bhvn-vp-sells-5000-shares-of-stock.html.

Biohaven Pharmaceutical Company Profile

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.

Insider Buying and Selling by Quarter for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply